Agentic AI Personalized Dietary Management Study (AIDiet)
Effectiveness of an Agentic AI-Based Personalized Dietary Management Algorithm in Health Screening Participants: A Randomized Controlled Trial
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Suyeon Choi, MD, PhD
- Numero di telefono: 02-2112-5639
- Email: 65390@snuh.org
Luoghi di studio
-
-
Seoul
-
Seoul, Seoul, Corea del Sud, 06236
- Reclutamento
- Seoul National University Hospital Healthcare System Gangnam Center
-
Contatto:
- Su-Yeon Choi, PhD
- Numero di telefono: +82-10-2028-5782
- Email: 65390@snuh.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Adults aged 20 years or older
- Individuals from the general population who underwent a health examination at the Seoul National University Hospital Healthcare System Gangnam Center
- Individuals who are capable of independently using a smartphone and operating study-related applications or text messaging functions
- Individuals without conditions that significantly interfere with standard dietary management, as specified in the exclusion criteria [Section 9.2 Exclusion Criteria]
Exclusion Criteria:
- Individuals unable to use a smartphone or study-related digital program/application, including those without a smartphone or unable to operate text messaging or application-based functions.
- End-stage renal disease or patients currently receiving dialysis
- Active cancer or currently undergoing chemotherapy or radiotherapy
- Severe heart failure, liver cirrhosis, or hepatic insufficiency accompanied by varices, bleeding, ascites, hepatic encephalopathy, or jaundice
- Malabsorption disorders such as Crohn's disease or short bowel syndrome
- Poorly controlled hyperthyroidism or hypothyroidism
- Diagnosed eating disorders or severe psychiatric disorders
- Pregnant or breastfeeding women, or women who may become pregnant during study participation.
- Individuals with recent major weight-related interventions or extreme body weight changes within the past 3 months, including:Bariatric surgery such as gastrectomy or gastric bypass surgery Newly initiated anti-obesity pharmacotherapy (e.g., semaglutide/Wegovy, tirzepatide/Mounjaro)
- Individuals considered by the investigator to have poor compliance potential or otherwise deemed unsuitable for participation in the clinical study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Nessun intervento: Control group
Participants receive standard dietary education and perform passive dietary recording during the 12-week study period.
|
|
|
Sperimentale: Static goal AI intervention group
Participants receive AI-generated personalized dietary goals that are maintained during the 12-week intervention period.
|
The AI algorithm generates individualized dietary goals based on baseline information.
The generated goals are maintained without dynamic adjustment during the intervention period.
|
|
Sperimentale: Adaptive goal AI intervention group
Participants receive adaptive AI-based dietary tracking, dynamic goal adjustment, and personalized feedback during the 12-week intervention period.
|
The AI algorithm monitors dietary records and relevant participant information, adjusts dietary goals dynamically, and provides personalized feedback to support dietary behavior change.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Dietary Behavior Score
Lasso di tempo: Baseline and 12 weeks
|
Dietary behavior will be assessed using a 12-item dietary behavior questionnaire derived from a 19-item dietary assessment questionnaire developed and routinely used at Seoul National University Hospital Gangnam Center.
Each item is scored on a 3-point scale (1, 3, or 5 points).
Total scores range from 12 to 60, with higher scores indicating healthier dietary behaviors.
The change in total dietary behavior score from baseline to 12 weeks will be evaluated.
unit:score
|
Baseline and 12 weeks
|
|
Outcome Measure: Change in Client Satisfaction Questionnaire Score (CSQ-8)
Lasso di tempo: from baseline to 12 weeks.
|
Participant satisfaction with the system will be assessed using the Client Satisfaction Questionnaire-8 (CSQ-8).
Total scores range from 8 to 32, with higher scores indicating greater satisfaction with the system.unit:score
|
from baseline to 12 weeks.
|
|
Change in System Usability Scale Score (SUS)
Lasso di tempo: from baseline to 12 weeks
|
System usability will be assessed using the System Usability Scale (SUS).
Total scores range from 0 to 100, with higher scores indicating better usability.
unit:score
|
from baseline to 12 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Body Mass Index
Lasso di tempo: Baseline and 12 weeks
|
Change in body mass index from baseline to 12 weeks.
Unit: kg/m²
|
Baseline and 12 weeks
|
|
Change in Waist Circumference
Lasso di tempo: from baseline to 12 weeks
|
Change in waist circumference from baseline to 12 weeks.
Unit : cm
|
from baseline to 12 weeks
|
|
Change in Systolic Blood Pressure
Lasso di tempo: from baseline to 12 weeks.
|
Change in systolic blood pressure from baseline to 12 weeks.Unit:mmHg
|
from baseline to 12 weeks.
|
|
Change in Diastolic Blood Pressure
Lasso di tempo: from baseline to 12 week
|
Change in diastolic blood pressure from baseline to 12 weeks.
Unit:mmHg
|
from baseline to 12 week
|
|
Change in Fasting Glucose
Lasso di tempo: from baseline to 12 weeks.
|
Change in fasting glucose from baseline to 12 weeks.
Unit:mg/dL
|
from baseline to 12 weeks.
|
|
Change in HbA1c
Lasso di tempo: from baseline to 12 week
|
Change in HbA1c from baseline to 12 weeks.Unit:%
|
from baseline to 12 week
|
|
Change in total cholesterol
Lasso di tempo: from baseline to 12 weeks
|
Changes in total cholesterol from baseline to 12 weeks.
unit: mg/dL
|
from baseline to 12 weeks
|
|
Change in AST
Lasso di tempo: from baseline to 12 weeks
|
Changes in AST from baseline to 12 weeks.unit:
U/L
|
from baseline to 12 weeks
|
|
Change in Body fat mass
Lasso di tempo: from baseline to 12 weeks
|
Changes in body fat mass from baseline to 12 weeks.
unit : kg
|
from baseline to 12 weeks
|
|
Change in skeletal muscle mass
Lasso di tempo: from baseline to 12 weeks
|
Changes in skeletal muscle mass from baseline to 12 weeks.
unit:kg
|
from baseline to 12 weeks
|
|
Change in percent body fat
Lasso di tempo: from baseline to 12 weeks.
|
Changes in percent body fat from baseline to 12 weeks.
unit:%
|
from baseline to 12 weeks.
|
|
Change in body weight (kg)
Lasso di tempo: from baseline to 12 weeks
|
Change in body weight from baseline to 12 weeks unit: kg
|
from baseline to 12 weeks
|
|
Changes in LDL cholesterol
Lasso di tempo: from baseline to 12 weeks
|
Changes in LDL cholesterol from baseline to 12 weeks.
unit: mg/dL
|
from baseline to 12 weeks
|
|
Changes in HDL cholesterol
Lasso di tempo: from baseline to 12 weeks
|
Changes in HDL cholesterol from baseline to 12 weeks.
unit: mg/dL
|
from baseline to 12 weeks
|
|
Changes in triglycerides
Lasso di tempo: from baseline to 12 weeks.
|
Changes in triglycerides from baseline to 12 weeks.
|
from baseline to 12 weeks.
|
|
Changes in ALT
Lasso di tempo: from baseline to 12 weeks
|
Changes in ALT from baseline to 12 weeks.unit:
U/L
|
from baseline to 12 weeks
|
|
Changes in γ-GTP
Lasso di tempo: from baseline to 12 weeks
|
Changes in γ-GTP from baseline to 12 weeks.unit:
U/L
|
from baseline to 12 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- H-2602-154-1723 (Altro identificatore: Seoul National University Hospital IRB)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .